← Back to Search

Chemokine Receptor Antagonist

A Study of CCX140-B in Subjects With FSGS

Phase 2
Waitlist Available
Research Sponsored by ChemoCentryx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12, and week 12 to week 24

Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia

Eligible Conditions
  • Focal Segmental Glomerulosclerosis
  • Glomerulosclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12, and week 12 to week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12, and week 12 to week 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline in Activated Partial Thromboplastin Time
Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration
Change From Baseline in Plasma Alanine Aminotransferase
+15 more
Secondary study objectives
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 and Week 24
Proportion of Subjects Achieving Complete or Partial Renal Remission at Week 12 and Week 24

Side effects data

From 2020 Phase 2 trial • 46 Patients • NCT03536754
27%
Oedema peripheral
9%
Blood creatinine increased
9%
Blood creatine phosphokinase increased
9%
Presyncope
9%
Headache
9%
Grip strength decreased
9%
Cough
9%
Renal impairment
9%
Oropharyngeal pain
9%
Rash generalised
9%
Nasopharyngitis
9%
Fatigue
9%
Herpes dermatitis
9%
Oedema
9%
Arthralgia
9%
Back pain
9%
Spinal osteoarthritis
9%
Abdominal pain
9%
Fall
100%
80%
60%
40%
20%
0%
Study treatment Arm
CCX140-B 5mg Open Label
CCX140-B 10mg Open Label
CCX140-B 5 mg
CCX140-B 10 mg
CCX140-B 15mg Open Label
Placebo Open Label
Placebo
CCX140-B 15 mg

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Group DExperimental Treatment1 Intervention
CCX140-B 15 mg twice daily (N=10)
Group II: Group CExperimental Treatment1 Intervention
CCX140-B 10 mg twice daily (N=10)
Group III: Group BExperimental Treatment1 Intervention
CCX140-B 5 mg once daily (N=10)
Group IV: Group APlacebo Group1 Intervention
Placebo (N=10)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CCX-140
Not yet FDA approved

Find a Location

Who is running the clinical trial?

ChemoCentryxLead Sponsor
17 Previous Clinical Trials
2,294 Total Patients Enrolled
Medpace, Inc.Industry Sponsor
96 Previous Clinical Trials
29,831 Total Patients Enrolled
Peter Staehr, MDStudy DirectorChemoCentryx
4 Previous Clinical Trials
2,295 Total Patients Enrolled
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top